Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 151 Florida 150 Arizona 96 Georgia 88 Illinois 70
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company59 AstraZeneca58 AbbVie48 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC39 Clear sponsor filter
State
California151 Florida150 Arizona96 Georgia88 Illinois70
All 44 states
Target enrolment
to

Trials with a site in Connecticut

59 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
Not yet open
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-08-12
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-22
Recruiting
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Active, closed
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Active, closed
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Active, closed
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Active, closed
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
Eli Lilly and Company
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Recruiting
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Active, closed
Eli Lilly and Company
Phase 2
414
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-09-21
Recruiting
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
By invitation
Eli Lilly and Company
Phase 3
333
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Recruiting
Eli Lilly and Company
Phase 3
595
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2023-02-27
Active, closed
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
Eli Lilly and Company
Phase 3
15,374
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Active, closed
Eli Lilly and Company
Phase 4
780
Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky
2022-08-01
Active, closed
Eli Lilly and Company
Phase 3
2,996
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-27
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire
2021-07-19
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Massachusetts, Missouri, New York, Pennsylvania, Texas
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
996
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Indiana
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,736
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2020-06-19
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Eli Lilly and Company
Phase 2
10,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2020-01-30
Active, closed
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2017-05-02
Active, closed
Eli Lilly and Company
Observational
1,400
California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas, Kentucky
2016-10-29
Active, closed
Eli Lilly and Company
Phase 2
110
Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland
2012-05-22
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Connecticut that also match the filters currently applied.

How many clinical trials are recruiting in Connecticut?

32 of the 59 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 24 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Connecticut), 59 studies
PhaseStudiesRecruitingShare
Phase 3371862.7%
Phase 2141123.7%
Phase 1325.1%
Phase 1/2315.1%
Observational101.7%
Phase 4101.7%

Most active sponsors

Lead sponsors with the most studies (Connecticut)
Lead sponsorStudiesRecruiting
Eli Lilly and Company5932
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.